Sunday, December 22, 2024
Subscribe American Journal of Medicine Free Newsletter
Pulmonarychronic obstructive pulmonary diseaseCOPD: To Be or Not to Be, That is the Question

COPD: To Be or Not to Be, That is the Question

Evolving models of lung function trajectories of chronic obstructive pulmonary disease (COPD). (A) represents the curves proposed by Fletcher and Peto2 in 1977 (modified with permission from the authors) showing accelerated decline of FEV1 among susceptible smokers who will develop disease by their mid-late adult life. (B) represents 4 lung function trajectories identified in the study by Lange et al6 (modified with permission from the authors) based on levels of FEV1 prior to the age of 40 years (below or above 80% of predicted value) and the presence or absence of COPD at the end of follow-up. Patients with COPD belong to one of 2 categories: the rapid decliners identified by the red line and individuals who do not decline faster than expected but start adult life with already established lung function deficits (black line). (C) represents 6 lung function trajectories identified in the study by Bui et al9 (reproduced with permission from the authors) in the population-based cohort of the Tasmanian Longitudinal Health Study. The 3 trajectories of “Early below average, accelerated decline,” “Persistently low,” and “Below average” accounted for 75% of COPD burden by age 53 years.

As our knowledge on the natural history of chronic obstructive pulmonary disease (COPD) progresses, a conceptual model simply based on an accelerated decline of lung function in adult life in response to smoking has become inadequate to capture the complexity of this disease, and increasing attention is being given to possible contributions from events or alterations of developmental processes that take place earlier in life. In addition, a remarkable heterogeneity has emerged among the pathobiological mechanisms that are involved in different phenotypes of COPD, suggesting that an effective disease management will require individualized treatment approaches largely based on the underlying biological mechanisms (endotypes). In this review, we will discuss the many faces of COPD from an epidemiological, pathobiological, and clinical standpoint and argue that airflow limitation encompasses a number of manifestations that are too diverse to be still clustered under the same diagnostic label.

To read this article in its entirety please visit our website.

-Francesca Polverino, MD, PhDa,b, Afshin Sam, MDa, Stefano Guerra, MD, PhDa,c

This article originally appeared in the November 2019 issue of The American Journal of Medicine.

Latest Posts

lupus

Sarcoidosis with Lupus Pernio in an Afro-Caribbean Man

A 54-year-old man of Afro-Caribbean ancestry presented with a 2-month history of nonproductive cough, 10-day history of constant subjective fevers, and a 1-day history...
Flue Vaccine

Flu Vaccination to Prevent Cardiovascular Mortality (video)

0
"Influenza can cause a significant burden on patients with coronary artery disease," write Barbetta et al in The American Journal of Medicine. For this...
varicella zoster

Varicella Zoster Virus-Induced Complete Heart Block

0
Complete heart block is usually caused by chronic myocardial ischemia and fibrosis but can also be induced by bacterial and viral infections. The varicella...
Racial justice in healthcare

Teaching Anti-Racism in the Clinical Environment

0
"Teaching Anti-Racism in the Clinical Environment: The Five-Minute Moment for Racial Justice in Healthcare" was originally published in the April 2023 issue of The...
Invisible hand of the market

The ‘Invisible Hand’ Doesn’t Work for Prescription Drugs

0
Pharmaceutical innovation has been responsible for many “miracles of modern medicine.” Reliance on the “invisible hand” of Adam Smith to allocate resources in the...
Joseph S. Alpert, MD

New Coronary Heart Disease Risk Factors

0
"New Coronary Heart Disease Risk Factors" by AJM Editor-in Chief Joseph S. Alpert, MD was originally published in the April 2023 issue of The...
Cardiovascular risk from noncardiac activities

Cardiac Risk Related to Noncardiac & Nonsurgical Activities

0
"Assessment of Cardiovascular Risk for Noncardiac and Nonsurgical Activities" was originally published in the April 2023 issue of The American Journal of Medicine. Cardiovascular risk...